论文部分内容阅读
目的 :分析大连市旅顺口区1991~2010年甲状腺癌发病趋势。方法 :对大连市旅顺口区疾病预防控制中心收集的本辖区1991~2010年户籍人口中甲状腺癌新发病例资料进行粗发病率、世界标准人口标化发病率、截缩率、累计率以及年度变化百分比(APC)的计算,并描述其时间、性别和年龄分布。结果:1991~2010年间,甲状腺癌新发病例288例,男、女性别比为1:3.72。男、女性粗发病率分别为2.90/10万、10.80/10万,APC分别为10.63%、15.84%,均有统计学意义;男、女性标化率分别为3.30/10万、7.90/10万,APC分别为13.88%、16.88%,均有统计学意义;男、女性35~64岁截缩率分别为4.52/10万、18.18/10万;男、女性0~64累计率分别为0.002%、0.011%,0~74累计率分别为0.003%、0.011%;男、女性发病率分别在80~84岁、55~59岁达到高峰。结论:旅顺口区男、女性甲状腺癌发病率均上升明显,男性APC均超过10%,女性APC均超过15%,建议加强三级预防策略来控制并减少甲状腺癌的发生和发展。
Objective: To analyze the trend of thyroid cancer incidence in Lushunkou District of Dalian from 1991 to 2010. Methods: The data of crude thyroid cancer incidence, the incidence rate of standardization of population in the world, the rate of truncation and the cumulative rate of annual thyroid cancer collected from 1991 to 2010 in this area collected by the Center for Disease Control and Prevention of Lushunkou District in Dalian City were collected. Change percentage (APC) calculations, and describe their time, gender, and age distribution. Results: Between 1991 and 2010, 288 new cases of thyroid cancer were found, with a male to female ratio of 1: 3.72. The crude incidence of males and females were 2.90 / lakhs, 10.80 / lakhs and APC were 10.63% and 15.84%, respectively, which were statistically significant. The standardized rates of males and females were 3.30 / lakhs and 7.90 / lakhs , APC were 13.88% and 16.88%, respectively, with statistical significance. The truncation rates of male and female 35-64 years were 4.52 / 100000 and 18.18 / 100000 respectively. The cumulative rates of male and female 0-64 were 0.002% , 0.011%, 0 ~ 74 cumulative rates were 0.003%, 0.011%; male and female incidence were 80 to 84 years old, 55 to 59 years old peaked. Conclusion: The incidence of thyroid cancer in both men and women in Lushunkou District increased significantly. Both male and female APC were over 10% and 15% respectively. It is suggested that tertiary prevention strategies should be taken to control and reduce the occurrence and development of thyroid cancer.